Diabetes drug repurposed to fight polycystic kidney disease
NCT ID NCT06391450
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 4 trial tests whether empagliflozin, a diabetes drug, can safely slow kidney growth and preserve kidney function in 44 adults with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Participants take either empagliflozin or a placebo for 18 months, and some also take the standard drug tolvaptan. The goal is to see if adding empagliflozin helps protect the kidneys.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- empagliflozin
- What this could lead to
- If it works, this could offer a new way to slow kidney enlargement and preserve kidney function in people with polycystic kidney disease.
- What could go wrong
- This is a small, early-phase trial with only 44 participants, so results may not apply to everyone. The drug may not show a clear benefit over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.